Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies

The prosocial neuropeptide oxytocin is being developed as a potential treatment for various neuropsychiatric disorders including autism spectrum disorder (ASD). Early studies using intranasal oxytocin in patients with ASD yielded encouraging results and for some time, scientists and affected familie...

Full description

Saved in:
Bibliographic Details
Main Authors: Althammer, Ferdinand (Author) , Muscatelli, Françoise (Author) , Grinevich, Valéry (Author) , Schaaf, Christian P. (Author)
Format: Article (Journal)
Language:English
Published: 08 August 2022
In: Translational Psychiatry
Year: 2022, Volume: 12, Pages: 1-11
ISSN:2158-3188
DOI:10.1038/s41398-022-02054-1
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41398-022-02054-1
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41398-022-02054-1
Get full text
Author Notes:Ferdinand Althammer, Francoise Muscatelli, Valery Grinevich, Christian P. Schaaf

MARC

LEADER 00000caa a2200000 c 4500
001 1838104321
003 DE-627
005 20230831101246.0
007 cr uuu---uuuuu
008 230303s2022 xx |||||o 00| ||eng c
024 7 |a 10.1038/s41398-022-02054-1  |2 doi 
035 |a (DE-627)1838104321 
035 |a (DE-599)KXP1838104321 
035 |a (OCoLC)1389534797 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Althammer, Ferdinand  |e VerfasserIn  |0 (DE-588)1141804689  |0 (DE-627)1000758591  |0 (DE-576)494519762  |4 aut 
245 1 0 |a Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes  |b evidence, disappointments, and future research strategies  |c Ferdinand Althammer, Francoise Muscatelli, Valery Grinevich, Christian P. Schaaf 
264 1 |c 08 August 2022 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 03.03.2023 
520 |a The prosocial neuropeptide oxytocin is being developed as a potential treatment for various neuropsychiatric disorders including autism spectrum disorder (ASD). Early studies using intranasal oxytocin in patients with ASD yielded encouraging results and for some time, scientists and affected families placed high hopes on the use of intranasal oxytocin for behavioral therapy in ASD. However, a recent Phase III trial obtained negative results using intranasal oxytocin for the treatment of behavioral symptoms in children with ASD. Given the frequently observed autism-like behavioral phenotypes in Prader-Willi and Schaaf-Yang syndromes, it is unclear whether oxytocin treatment represents a viable option to treat behavioral symptoms in these diseases. Here we review the latest findings on intranasal OT treatment, Prader-Willi and Schaaf-Yang syndromes, and propose novel research strategies for tailored oxytocin-based therapies for affected individuals. Finally, we propose the critical period theory, which could explain why oxytocin-based treatment seems to be most efficient in infants, but not adolescents. 
650 4 |a Autism spectrum disorders 
650 4 |a Medical genetics 
650 4 |a Molecular neuroscience 
700 1 |a Muscatelli, Françoise  |e VerfasserIn  |0 (DE-588)1170113427  |0 (DE-627)1037100840  |0 (DE-576)512391319  |4 aut 
700 1 |a Grinevich, Valéry  |e VerfasserIn  |0 (DE-588)1158696574  |0 (DE-627)1020774606  |0 (DE-576)504314289  |4 aut 
700 1 |a Schaaf, Christian P.  |d 1978-  |e VerfasserIn  |0 (DE-588)130397318  |0 (DE-627)500686025  |0 (DE-576)298170345  |4 aut 
773 0 8 |i Enthalten in  |t Translational Psychiatry  |d London : Nature Publishing Group, 2011  |g 12(2022), Artikel-ID 318, Seite 1-11  |h Online-Ressource  |w (DE-627)660807378  |w (DE-600)2609311-X  |w (DE-576)345003462  |x 2158-3188  |7 nnas  |a Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes evidence, disappointments, and future research strategies 
773 1 8 |g volume:12  |g year:2022  |g elocationid:318  |g pages:1-11  |g extent:11  |a Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes evidence, disappointments, and future research strategies 
856 4 0 |u https://doi.org/10.1038/s41398-022-02054-1  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.nature.com/articles/s41398-022-02054-1  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20230303 
993 |a Article 
994 |a 2022 
998 |g 130397318  |a Schaaf, Christian P.  |m 130397318:Schaaf, Christian P.  |d 910000  |d 911500  |e 910000PS130397318  |e 911500PS130397318  |k 0/910000/  |k 1/910000/911500/  |p 4  |y j 
998 |g 1158696574  |a Grinevich, Valéry  |m 1158696574:Grinevich, Valéry  |d 60000  |e 60000PG1158696574  |k 0/60000/  |p 3 
998 |g 1141804689  |a Althammer, Ferdinand  |m 1141804689:Althammer, Ferdinand  |d 910000  |d 911500  |e 910000PA1141804689  |e 911500PA1141804689  |k 0/910000/  |k 1/910000/911500/  |p 1  |x j 
999 |a KXP-PPN1838104321  |e 4283150010 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"subtitle":"evidence, disappointments, and future research strategies","title":"Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes","title_sort":"Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes"}],"person":[{"family":"Althammer","role":"aut","roleDisplay":"VerfasserIn","given":"Ferdinand","display":"Althammer, Ferdinand"},{"display":"Muscatelli, Françoise","roleDisplay":"VerfasserIn","role":"aut","given":"Françoise","family":"Muscatelli"},{"given":"Valéry","role":"aut","roleDisplay":"VerfasserIn","display":"Grinevich, Valéry","family":"Grinevich"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Christian P.","display":"Schaaf, Christian P.","family":"Schaaf"}],"language":["eng"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"08 August 2022"}],"name":{"displayForm":["Ferdinand Althammer, Francoise Muscatelli, Valery Grinevich, Christian P. Schaaf"]},"id":{"eki":["1838104321"],"doi":["10.1038/s41398-022-02054-1"]},"physDesc":[{"extent":"11 S."}],"relHost":[{"id":{"eki":["660807378"],"zdb":["2609311-X"],"issn":["2158-3188"]},"recId":"660807378","part":{"volume":"12","text":"12(2022), Artikel-ID 318, Seite 1-11","pages":"1-11","year":"2022","extent":"11"},"note":["Gesehen am 17.05.11"],"pubHistory":["1.2011 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Translational Psychiatry","title_sort":"Translational Psychiatry"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"London","dateIssuedKey":"2011","dateIssuedDisp":"2011-","publisher":"Nature Publishing Group"}],"language":["eng"],"disp":"Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes evidence, disappointments, and future research strategiesTranslational Psychiatry"}],"note":["Gesehen am 03.03.2023"],"recId":"1838104321","type":{"bibl":"article-journal","media":"Online-Ressource"}} 
SRT |a ALTHAMMERFOXYTOCINBA0820